Related by context. All words. (Click for frequent words.) 61 null responder 61 CIMZIA TM certolizumab pegol 60 BRAF inhibitor 60 recurrent glioblastoma multiforme 60 ZACTIMA 60 Novartis Zometa 60 cediranib 60 invasive aspergillosis 60 NSABP 60 invasive candidiasis 59 Xelox 59 BR.# 59 allogeneic HSCT 59 heparin induced thrombocytopenia 59 constipation OIC 59 RE LY trial 59 prospective nonrandomized 59 Thal Dex 59 HBeAg 59 Trandolapril 59 visceral metastases 59 oral Hycamtin 59 Crohns disease 59 PROactive study 59 Hormone Refractory Prostate Cancer 59 sorafenib Nexavar 59 hepatorenal syndrome 59 underwent resection 59 Endarterectomy 59 Juvenile Idiopathic Arthritis 59 PRoFESS 59 Revlimid lenalidomide 59 CP CPPS 58 interferon ribavirin 58 standard chemotherapy regimen 58 MADIT CRT trial 58 cetuximab Erbitux 58 dual endothelin receptor antagonist 58 stage IIIb IV 58 chronic myeloid 58 Hematologic 58 pain palliation 58 Torisel 58 HIV HCV coinfected 58 cancer mCRC 58 biliary tract cancer 58 CMV retinitis 58 MADIT CRT 58 gefitinib Iressa 58 sJIA 58 pancreatic islet cell 58 ACUITY trial 58 aromatase inhibitors AIs 58 GOUT 58 deep venous thromboses 58 psoriatic arthritis PsA 58 metastatic renal 58 cinacalcet 58 basal cell carcinoma BCC 58 venous thromboembolic disease 58 tipranavir 58 mycosis fungoides 58 Surgical resection 58 trastuzumab Herceptin ® 58 Chronic lymphocytic leukemia 58 RezularTM 58 clevidipine 58 antiarrhythmic 58 iniparib 58 carotid artery stenting CAS 57 NATRECOR ® 57 pertuzumab 57 Carotid Revascularization Endarterectomy vs. 57 angiogenesis inhibition 57 ACTEMRA TM 57 trastuzumab DM1 57 resected pancreatic cancer 57 HORIZONS AMI trial 57 phase IIIb 57 Gleevec imatinib 57 colorectal adenoma 57 randomized multicenter trial 57 cisplatin vinorelbine 57 urothelial cancer 57 Patency 57 abacavir Ziagen 57 RE LY 57 Randomized Study 57 stratifying patients 57 chronic GVHD 57 MAGE A3 ASCI 57 pegylated liposomal doxorubicin 57 malignant pleural mesothelioma 57 myelodysplastic myeloproliferative diseases 57 mycophenolate mofetil 57 gastrointestinal stromal tumors GIST 57 BARACLUDE ® 57 relapsing multiple sclerosis 57 KRAS status 57 prospectively stratified 57 clinicopathological 57 relapsing remitting MS RRMS 57 unresectable HCC 57 angiographically 57 nonmetastatic 57 ASTEROID 57 neurologic progression 57 FOLFOX4 57 EGFR mutation positive 57 eosinophilic asthma 57 nonmelanoma skin cancers 57 differentiated thyroid 57 riociguat 57 rFVIIa 57 eculizumab therapy 57 phase IIb trial 57 anti angiogenic therapy 57 landmark ATHENA trial 57 Cimzia TM 56 Prostate AdenoCarcinoma Treatment 56 relapsed MM 56 Renal Cell Carcinoma RCC 56 de novo AML 56 Instanyl 56 Stage IIIb 56 Aggressive Reduction 56 nonsmall cell lung cancer 56 induce orthostatic hypotension 56 Velcade bortezomib 56 ExTRACT TIMI 56 headache nasopharyngitis 56 antithrombotic therapy 56 gemcitabine carboplatin 56 ritonavir boosted 56 Roche Xeloda 56 ankylosing spondylitis AS 56 HeFH 56 prospectively enrolled 56 ATACAND 56 pediatric acute lymphoblastic 56 completely resected 56 HuMax EGFr 56 juvenile idiopathic arthritis JIA 56 HER2 amplified 56 T1c 56 DAPT 56 primary hyperparathyroidism 56 fosbretabulin 56 chronic thromboembolic pulmonary 56 multiple myeloma MM 56 pulmonary arterial hypertension PAH 56 CYPHER Stent 56 complete cytogenetic response 56 hepatic encephalopathy HE 56 SSc 56 Digital Mammographic Imaging 56 overactive bladder syndrome 56 Dr. Kandzari 56 gonococcal 56 BPS IC 56 demonstrated antitumor activity 56 Subgroup analysis 56 Acute myeloid leukemia 56 VADT 56 Doxil ® 56 complement inhibitor eculizumab 56 childhood acute lymphoblastic 56 Acute Myocardial Infarction 56 lung fibrosis 56 Zolinza 56 T1a 56 diabetic gastroparesis 56 BCIRG 56 transplantation HCT 56 EVEREST II 56 Heart Failure Trial 56 Valsartan 56 chronic periodontitis 56 HBeAg negative 56 gadobutrol 56 cytotoxic therapy 56 β blockers 56 adjuvant colon cancer 56 Helicobacter pylori eradication 56 virologic response 56 nadroparin 56 KRAS mutation 56 Chronic Sinusitis 56 Gleevac 56 gastric adenocarcinoma 56 macrovascular events 56 APPRAISE 56 LV dysfunction 56 recurrent metastatic 56 thromboembolic disease 56 erosive GERD 56 CombAT 56 Pertuzumab 56 undetectable HBV DNA 56 malignant neoplasm 56 STRIDE PD 56 intravenous cyclophosphamide 56 anagrelide 56 DASISION 56 PsA 56 chronic myocardial ischemia 56 Edge STudy 56 AA Amyloidosis 56 symptomatic intracranial 55 SCD HeFT 55 SNT MC# 55 histologic subtype 55 randomized Phase IIb 55 valvular heart 55 variceal bleeding 55 CYPHER ® Stent 55 leukemia AML 55 idiopathic thrombocytopenic purpura 55 Myocardial Infarction 55 relapsed ALL 55 deferiprone 55 clinical pharmacology studies 55 gastrointestinal perforation 55 postoperative atrial fibrillation 55 ZOLINZA 55 liver transplant recipients 55 rheumatologic 55 MabThera rituximab 55 autologous transplantation 55 postoperative AF 55 Femara letrozole 55 nulliparous women 55 OHR/AVR# 55 trastuzumab emtansine T DM1 55 morphometric vertebral fractures 55 cytomegalovirus infection 55 ruboxistaurin 55 NSABP C 55 relapsed multiple myeloma 55 Chronic Prostatitis 55 Kepivance 55 NSABP B 55 idiopathic myelofibrosis 55 Ischemic 55 metastatic CRC 55 autologous transplants 55 radiochemotherapy 55 Gynecologic Oncology Group 55 metastatic bone 55 inhaled corticosteroid therapy 55 PHPT 55 refractory metastatic 55 urolithiasis 55 Effexor venlafaxine 55 venlafaxine Effexor 55 vidofludimus 55 pelvic lymphadenectomy 55 pancreatic adenocarcinoma 55 lichen planus 55 Randomised Study 55 Inhaled nitric oxide 55 placebo controlled clinical 55 mRCC 55 metastatic gastric 55 Patient Outcomes 55 angiographic outcomes 55 recurrent DVT 55 darunavir r 55 osteoporotic compression fractures 55 Folfox 55 Hepatocellular Carcinoma HCC 55 subanalysis 55 canakinumab 55 quinolone 55 ischemic mitral regurgitation 55 trabectedin 55 iniparib BSI 55 Stent thrombosis 55 carcinoid 55 phase IIb clinical 55 relapsed ovarian cancer 55 Cinquil 55 stage IIIB IV 55 BrachySil TM 55 parkinsonian symptoms 55 Ziprasidone 55 antiangiogenic therapy 55 CCyR 55 hypercholesterolaemia 55 genotypic resistance 55 Chronic Bronchitis 55 relapsed SCLC 55 SJIA 55 ToGA 55 coronary intervention 55 ER CHOP 55 glucocorticoid induced osteoporosis 55 pharmacokinetic PK study 55 aromatase inhibitor therapy 55 antithrombotics 55 HBeAg negative patients 55 multicenter randomized controlled 55 radiographic outcomes 55 juvenile idiopathic arthritis 55 NSAID induced 55 metastatic malignant melanoma 55 patientswith 55 Degarelix 55 intra abdominal abscess 55 Naive Patients 55 neurologic complications 55 infective endocarditis 55 thrombocytopenic 55 favorable tolerability 55 Phase IIIb clinical 55 metastatic kidney 55 hematological malignancy 55 atherothrombotic disease 55 squamous histology 55 TAXUS IV 55 Adjuvant chemotherapy 55 androgen ablation 55 Nesiritide 55 FOLFIRINOX 55 bevacizumab Avastin 55 Faslodex 55 paclitaxel carboplatin 55 superficial bladder cancer 55 post thrombotic syndrome 55 nondiabetic patients 55 antirheumatic 55 recurrent GBM 55 baseline LDH 55 clazosentan 55 vaso occlusive crisis 55 Tiotropium 55 nicardipine 55 receptor tyrosine kinase inhibitor 55 prostate cancer PCa 55 neovascular diseases 55 Subgroup analyzes 55 thrombocytosis 55 mechanically ventilated patients 55 nonsquamous 55 cranial irradiation 55 intensive statin therapy 55 salmeterol fluticasone 55 unresectable tumors 55 zotarolimus eluting stent 55 Coronary Artery Bypass Graft 54 RE LY ® 54 Microplasmin 54 recurrent herpes labialis 54 deletion 5q 54 Secondary efficacy endpoints 54 BEXXAR Therapeutic Regimen 54 anemia thrombocytopenia 54 Safinamide 54 ACTEMRA 54 Losartan 54 Sjögren syndrome 54 NATRECOR R 54 labetalol 54 Venous thromboembolism 54 aripiprazole Abilify 54 pouchitis 54 ixabepilone 54 brivaracetam 54 Retreatment 54 Hydroxyurea 54 leukemia ALL 54 PROLARIS 54 histologic subtypes 54 Cholesterol Levels SPARCL 54 Elitek 54 terlipressin 54 dacarbazine chemotherapy 54 retrospective cohort 54 secondary hyperparathyroidism 54 cardio renal 54 CARE HF 54 alfuzosin 54 chemoprevention trials 54 antireflux surgery 54 thrombotic complications 54 Avandia Actos 54 Protelos 54 bullous 54 Trovax 54 proliferative retinopathy 54 multicenter prospective 54 endocrine therapies 54 Wilms tumors 54 oral ridaforolimus 54 levosimendan 54 liver resection 54 renal artery stenting 54 thiopurine 54 antibiotic regimens 54 Sipuleucel T 54 cerebral vasospasm 54 Ophena TM 54 valvular heart disease 54 artery stenosis 54 HER2 positive metastatic breast 54 dalteparin 54 Complications Trial 54 inhibitor RG# 54 prostate cancer CaP 54 Phase IIb clinical trials 54 RoACTEMRA 54 antiretroviral naïve 54 KRAS mutations occur 54 Severe Sepsis 54 Waldenstrom macroglobulinemia 54 bowel resection 54 Troxatyl 54 dexpramipexole 54 antihormonal 54 renal denervation 54 forodesine 54 liver metastasis 54 #mg BID [001] 54 acute GVHD 54 Fabry Disease 54 cranial radiation 54 Halaven 54 antiplatelet drugs 54 placebo controlled studies 54 fragility fractures 54 CIPN 54 platinum refractory 54 comorbid depression 54 ARCOXIA 54 sunitinib malate 54 EGFR mutation status 54 oblimersen 54 multicenter Phase II 54 CALGB 54 intracerebral haemorrhage 54 intracranial stenosis 54 TMC# r 54 Campath alemtuzumab 54 bexarotene 54 Tocilizumab 54 relapsed GBM 54 5-FU/LV 54 % CI #.#-#.# [003] 54 Natalizumab 54 heavily pretreated 54 adjuvant therapies 54 T1DM 54 Dacogen injection 54 taxane therapy 54 temsirolimus 54 RAPAFLO R 54 prophylactic cranial irradiation 54 fibromyalgia syndrome 54 fallopian tube carcinoma 54 Amrubicin 54 sertraline Zoloft 54 colorectal liver metastases 54 OVATURE 54 operable breast cancer 54 randomized multicenter Phase III 54 autonomic dysfunction 54 anemia neutropenia 54 elacytarabine 54 INTERHEART study 54 multivessel coronary artery 54 perioperative complications 54 evaluating Nexavar 54 Nilotinib 54 pulmonary metastasis 54 chronic prostatitis 54 biologic therapy 54 vWD 54 NEVO ™ 54 neoadjuvant treatment 54 pregabalin Lyrica 54 G6PD deficiency 54 antiplatelet medication 54 bisoprolol 54 atrasentan 54 cisplatin gemcitabine 54 pramlintide metreleptin combination 54 Vectibix panitumumab 54 evaluating mipomersen 54 postoperative radiotherapy 54 MitraClip device 54 liposomal amphotericin B 54 reflux esophagitis 54 IOP lowering 54 underwent surgical resection 54 atherosclerotic renal artery stenosis 54 receiving XGEVA 54 Acute Coronary Syndromes ACS 54 chronic HBV 54 histologies 54 HIPEC 54 Celgene Revlimid 54 YERVOY 54 DU #b 54 prospective multicenter study 54 EURIDIS 54 diffuse intrinsic pontine glioma 54 IV malignant melanoma 54 HORIZONS AMI 54 rosuvastatin Crestor 54 chemotherapeutic regimen 54 hemodialysis patients 54 mg/m2 dose 53 GAMMAGARD 53 anti angiogenic agents 53 Advagraf 53 motesanib 53 autologous SCT 53 HCV RESPOND 2 53 SPIRIT FIRST 53 surgical debulking 53 mutated KRAS 53 PAOD 53 oral anticoagulation 53 Hypotension 53 Phase IIIb 53 Prospective Randomized 53 agomelatine 53 multifactorial disease 53 Phase IIb III 53 clinically meaningful improvements 53 Neoadjuvant 53 XIENCE V demonstrated 53 medically refractory 53 antiplatelet therapies 53 AVAPRO 53 nausea vomiting headache 53 HNSCC 53 Cell Lymphoma CTCL 53 aldosterone antagonists 53 ORMD 53 IPAH 53 CANCIDAS 53 extracapsular extension 53 pulmonary hypertension PH 53 quetiapine Seroquel 53 Combination therapy 53 NCCN guidelines 53 atopic disease 53 Myelodysplastic syndromes MDS 53 antiemetics 53 SABCS 53 refractory CLL 53 portal vein thrombosis 53 doxorubicin docetaxel 53 HYVET 53 zalutumumab 53 intravascular hemolysis 53 BREVAGen ™ 53 VaD 53 imipramine Tofranil 53 SORT OUT III 53 Gefitinib 53 pelvic malignancies 53 exemestane Aromasin 53 randomized controlled clinical 53 perinatal outcomes 53 paclitaxel poliglumex 53 AOD# [002] 53 multicentric 53 prospective randomized multicenter 53 Candida infection 53 thetreatment 53 coronary stenting 53 cardiac revascularization 53 axitinib 53 Bosentan 53 locoregional recurrence 53 malignant neoplasms 53 Candesartan 53 multivessel disease 53 Mestinon 53 irinotecan chemotherapy 53 proliferative diabetic retinopathy 53 idraparinux 53 diabetic polyneuropathy 53 octreotide implant 53 QTc prolongation 53 intravesical therapy 53 symptomatic VTE 53 concurrent chemoradiation 53 Chronic Myelogenous Leukemia CML 53 oxycodone CR 53 knee osteoarthritis OA 53 non squamous NSCLC 53 placebo controlled trials 53 adverse cytogenetics 53 Prostatitis 53 IMPACT DCM 53 Canvaxin 53 acute lymphoblastic 53 Alzheimer Disease AD 53 osteoporotic vertebral fractures 53 adjuvant cisplatin 53 unresectable stage 53 COREG 53 Randomized Evaluation 53 Captopril 53 prazosin 53 posttransplant 53 ependymoma 53 chemoradiotherapy 53 ECASS 53 gastro intestinal disorders 53 histological subtype 53 monoclonal gammopathy 53 noninferiority 53 taxotere 53 pegylated interferon alfa 2b 53 glucocorticoid therapy 53 enzastaurin 53 colorectal cancer CRC 53 QUASAR validation study 53 elotuzumab 53 Betaferon ® 53 radiographic progression 53 Systemic Lupus Erythematosus 53 CHAMPION PCI 53 Adjuvant therapy 53 UPLYSO 53 Tasimelteon 53 F FDG PET 53 paricalcitol 53 candesartan 53 Acute Myeloid Leukaemia AML 53 phase IIa 53 recurrent glioma 53 grade cervical intraepithelial 53 Zemplar Capsules 53 galiximab 53 chemoradiation therapy 53 Cardio vascular 53 periprocedural MI 53 TAXUS ATLAS 53 ELACYT 53 leukoencephalopathy 53 null responder HCV 53 TMP SMX 53 VFEND 53 pharmacogenetic testing 53 cytogenic 53 atherogenic dyslipidemia 53 IV NSCLC 53 ADAGIO study 53 MADIT 53 Multicenter 53 carotid stents 53 Acute Ischemic Stroke 53 metastatic lung cancer 53 anti arrhythmic drug 53 plus dexamethasone 53 thoracic aortic disease 53 Sezary syndrome 53 IBS C 53 VTE prophylaxis 53 post herpetic neuralgia PHN 53 FOLFIRI alone 53 #F FDG PET 53 anterior uveitis 53 COPD exacerbations 53 Overactive Bladder 53 Aortic stenosis 53 Prestara 53 commercialize deforolimus 53 Severe Primary IGFD 53 skeletal metastases 53 peritoneal carcinomatosis 53 undergone radical prostatectomy 53 evaluating REVLIMID 53 Dabigatran 53 relapsed AML 53 trabedersen 53 rituximab refractory 53 diabetic peripheral neuropathy DPN 53 lung metastasis 53 OPCAB 53 NCT# ClinicalTrials.gov 53 dopaminergic therapy 53 ASCEND HF 53 Abilify aripiprazole 53 intermittent claudication 53 ONTARGET 53 pharmacokinetic interaction 53 Chronic Fatigue Syndrome CFS 53 strontium ranelate 53 virologic failure 53 atherosclerotic vascular disease 53 diabetic microvascular complications 53 EORTC 53 tachyarrhythmias 53 OAB symptoms 53 Acute Renal Failure 53 ABSORB trial 53 metastatic RCC 53 DMIST 53 LymphoStat B belimumab 53 mutated K ras 53 hepatic cirrhosis 53 postmenopausal osteoporotic women 53 underwent liver transplantation 53 Atopic Dermatitis 53 Major Depressive Disorder MDD 53 post operative ileus 53 candidemia 53 ACTOS ® 53 pyridostigmine 53 ANCA associated 53 oral diclofenac 53 assessing T DM1 53 PTK# 53 adenoma recurrence 53 Avastin bevacizumab 53 hyperparathyroidism 53 invasive lobular carcinoma 53 Phase IIIb study 53 Frovatriptan 53 metaanalysis 53 recurrent venous thromboembolism 53 ADPKD 53 cystoid macular edema 53 MERLIN TIMI 53 ErbB2 positive 53 hypovitaminosis D 53 multicenter phase 53 SPIRIVA ® 53 nonalcoholic steatohepatitis NASH 53 cytoreduction 53 Juvenile Idiopathic Arthritis JIA 53 EGFR TKI 53 radioiodine therapy 53 multicenter randomized placebo controlled 53 Zyprexa olanzapine 53 Her2 positive 53 constipation predominant irritable bowel 53 multicenter trials 53 postoperative delirium 53 debulking surgery 53 reflux disease GERD 53 lipid parameters 53 recurrent malignant glioma 53 glatiramer acetate 53 OvaRex ® MAb 53 EDEMA3 52 optic neuropathy 52 Lamotrigine 52 euthymic patients 52 Langerhans cell histiocytosis 52 gp# vaccine 52 Ceflatonin 52 rheumatic arthritis 52 biliary cancer 52 OvaRex 52 therapeutic regimens 52 pharmacodynamic PD 52 post herpetic 52 Chemotherapy induced 52 relapsing MS 52 immunosuppressive regimen 52 perioperatively 52 prognostic variables 52 rheumatic diseases 52 metastatic renal cell carcinoma 52 systolic hypertension 52 levodopa induced 52 medically inoperable 52 randomized controlled clinical trials 52 Enbrel Humira 52 CTAP# Capsules 52 EGFR inhibitors 52 adrenalectomy 52 nasopharyngitis headache 52 SWOG 52 cardiac allograft vasculopathy 52 ENDEAVOR IV 52 radiolabeled TM# 52 GI motility disorders 52 nasal polyposis 52 trospium 52 Afib 52 Myelofibrosis 52 histologically proven 52 smoldering multiple myeloma 52 mildly symptomatic 52 primary dysmenorrhoea 52 OZURDEX ® 52 balloon kyphoplasty 52 atazanavir ritonavir 52 treatmentof 52 GISTs 52 DPNP 52 Novartis Reclast 52 PROCRIT therapy 52 Alocrest 52 ischemic cardiomyopathy 52 EGFR blockers 52 Rheumatoid Arthritis RA 52 Li Fraumeni 52 placebo controlled Phase III 52 endocrine responsive 52 PPAR gamma agonists 52 Bronchial Thermoplasty 52 polyp recurrence 52 Allergic Rhinitis 52 clinicopathological features 52 idiopathic thrombocytopenic purpura ITP 52 intravenous diuretics 52 desvenlafaxine succinate 52 Bronchiectasis 52 binary restenosis 52 thymic carcinoma 52 asthma allergic rhinitis 52 Quinamed 52 trials RCTs 52 olaparib 52 adjuvant radiotherapy 52 observational cohort study 52 Controlled Trial 52 overactive bladder symptoms 52 DCCR 52 ancrod 52 hepatic fibrosis 52 metastatic neuroendocrine tumors 52 CIN2 + 52 dermatologic reactions 52 gynaecologic 52 IRESSA 52 bone metastasis 52 postoperative mortality 52 extrapyramidal symptoms 52 SVR# 52 aleglitazar 52 antihypertensive therapy 52 oncological outcomes 52 rALLy 52 Observational Study 52 headache abdominal pain 52 TAXUS Liberte Stent 52 GnRH agonists 52 Sorafenib HCC Assessment 52 clinically evaluable 52 ADVANCE PD 52 DEFLUX 52 idiopathic PAH 52 Prognostic factors 52 Carvedilol 52 Topiramate 52 pharmacologic treatments 52 oral deforolimus 52 lupus anticoagulant 52 solid organ transplantation 52 GRN# 52 dyslipidaemia 52 Irritable Bowel Syndrome IBS 52 fibrinolysis 52 Erbitux cetuximab 52 Val HeFT 52 TroVax ® 52 deforolimus 52 HERCEPTIN 52 renal transplantation 52 Rheumatologists 52 methotrexate monotherapy 52 NSCL cancer 52 Endovascular Valve Edge 52 cilostazol 52 femoral neck fracture 52 Stage IIB 52 NOMID 52 decitabine 52 CHARISMA trial 52 TAXUS V 52 metastatic renal cell 52 farletuzumab 52 spinal metastases 52 ADHF 52 pT3 52 polyarticular 52 neovascular 52 micafungin 52 nephron sparing surgery 52 beta blocker therapy 52 THALOMID 52 severe exacerbations 52 anticoagulant warfarin 52 functional mitral regurgitation 52 Ivabradine 52 pancreatectomy 52 anastrozole Arimidex 52 myeloablative 52 LUX Lung 52 testosterone supplementation 52 landmark ATHENA 52 ADVEXIN therapy 52 CALGB # [001] 52 biochemical recurrence 52 HSCT 52 hepatologists 52 chemoresistance 52 nonrandomized 52 EGS# 52 BARI 2D 52 squamous cell histology 52 Acne Rosacea 52 Acute Myocardial Infarction AMI 52 icatibant 52 induce remission 52 protease inhibitor PI 52 TAXUS VI 52 recurrent glioblastoma 52 myelogenous leukemia 52 cardiac dysfunction 52 AVOREN 52 immunomodulatory therapy 52 coinfected patients 52 efalizumab 52 lumiliximab 52 metastatic ovarian cancer 52 ABVD 52 androgen deprivation 52 Recurrent Chest Wall 52 mucosal inflammation 52 biochemical relapse 52 thromboprophylaxis 52 adjunctive placebo 52 neurocognitive function 52 Thrombolysis 52 Diabetic Neuropathy 52 pentoxifylline 52 Hemodynamic 52 Glaxo Tykerb 52 afatinib 52 glycated hemoglobin levels 52 Moxifloxacin 52 TRANSFORMS 52 Bosutinib 52 pharmacologic therapies 52 radical retropubic prostatectomy 52 leukotriene receptor antagonists 52 prospective multicentre 52 Myocardial Infarction Study 52 ALND 52 Barrett esophagus BE 52 CLARITY study 52 velafermin 52 Angioedema 52 Acute myeloid leukemia AML 52 HCV SPRINT 52 nonvertebral fracture 52 histologically confirmed 52 OvaRex MAb 52 Diabetic nephropathy 52 longitudinal cohort study 52 Screening Trial DMIST 52 Percutaneous vertebroplasty 52 atopic dermatitis AD 52 systemic ALCL 52 pancreatic resection 52 Diabetes Interventions 52 paroxysmal AF 52 Mohs micrographic surgery 52 HPTN 52 sensory neuropathy 52 PROSTVAC ® 52 tenecteplase 52 esophagogastric 52 intravenous bisphosphonates 52 Motesanib 52 abnormal cytology 52 Rosuvastatin 52 Edwards SAPIEN valve 52 Tavocept 52 carotid artery blockage 52 randomized controlled trials RCTs 52 pulmonary exacerbation 52 sustained virologic response 52 prostate cancer CRPC 52 Stenting Trial CREST 52 Betaferon R 52 Cognitive impairment 52 SYNTAX 52 unstable angina UA 52 #mg dosing group 52 metastatic hormone refractory 52 multicenter placebo controlled 52 venlafaxine XR 52 Randomized trials 52 pCR 52 Multicenter Automatic Defibrillator Implantation 52 Stenting Trial 52 metabolic parameters